University of Pittsburgh
Home > Directory > Primary Faculty > Lin Zhang, PhD
Lin Zhang, PhD

Professor

2.42a Hillman Cancer Center
Pittsburgh, PA 15232
zhanglx@upmc.edu
Phone: 412-623-1009
Fax: 412-623-7778

Education

BS (Biochemistry), Sichuan University, Chengdu, P.R. China, 1990 PhD (Molecular Biology), University of Southern California, 1995 Postdoctoral Fellow, Johns Hopkins Oncology Center, 1995-1999
Lin Zhang, PhD

The immediate goal of our research is to understand how anticancer drugs kill cancer cells, and more importantly, why they fail so often.  In the long term, we will attempt to use this knowledge to identify novel molecular targets and treatment strategies to improve cancer chemotherapy and chemoprevention.

Cell death in anticancer therapies

Our research program has centered on several molecules that control discrete steps of programmed cell death. The first one, PUMA, is a downstream target of the tumor suppressor p53 and a BH3-only Bcl-2 family protein.  PUMA is required for DNA damage-induced and p53-dependent apoptosis, and also plays a key role in apoptosis induced by several targeted anticancer drugs.  The second one, SMAC, is a mitochondrial apoptogenic protein and a caspase activator.  SMAC helps to execute apoptosis induced by anticancer drugs via a mitochondrial feedback loop.  Regulators of non-apoptotic cell death, such as the autophagy inducer Beclin 1 and the necrosis regulator RIPK3, have also been studied.  Through analyses of these molecules and their associated protein networks, we try to gain deep understanding on how cell death is initiated and executed in human cancer cells, why some cancer cells are not sensitive to anticancer drugs, and what can be done to restore their sensitivity.

Oncogenic stem cells as the target of cancer chemoprevention

Prevention of human cancer through the use of chemical agents such as non-steroidal anti-inflammatory drugs (NSAIDs) has emerged as a promising strategy to reduce morbidity and mortality of cancer.  Our recent studies showed that intestinal stem cells that have acquired oncogenic alterations are targeted by NSAIDs in chemoprevention of colon cancer.  We are investigating how NSAIDs trigger apoptosis in such oncogenic stem cells, and if induction of apoptosis is critical for the chemopreventive effects of NSAIDs.  We will also determine if apoptosis regulators can be used as markers to predict outcomes of chemoprevention of cancer patients, and if manipulation of apoptosis regulators can be used to improve the chemopreventive effects of NSAIDs.

Manipulation of cell death regulators

To target PUMA, we have developed a high-throughput screening system for identifying small molecules that can activate PUMA in p53-deficient cancer cells.  In collaboration with the Pittsburgh Drug Discovery Institute, we will screen compound libraries to identify novel PUMA inducers.  We have also identified and characterized small molecules that mimic the functional domains of PUMA and SMAC.  Efforts are undertaken to apply these small molecules to chemotherapy and chemoprevention.

Journal Articles

Tong J, X Zheng, X Tan, R Fletcher, Z Nikolovska-Coleska, J Yu and L Zhang.  Mcl-1 phosphorylation without degradation mediates sensitivity to HDAC inhibitors by liberating BH3-only proteins. Cancer Research 78: 4704-4715, 2018.
 
Chen D, J Tong, L Yang, L Wei, DB Stolz, J Yu, J Zhang and L Zhang.  PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors. Proc. Natl. Acad. Sci. USA. 115: 3930-3935, 2018.
 
Knickelbein K, J Tong, D Chen, YJ Wang, S Misale, A Bardelli, J Yu and L Zhang.  Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene. 37:4599-4610, 2018.
 
Fletcher R, YJ Wang, RE Schoen, OJ Finn, J Yu, and L Zhang.  Colorectal cancer prevention: immune modulation taking the stage.  BBA - Reviews on Cancer. 1869:138-148, 2018.
 
Leibowitz BJ, L Yang, L Wei, ME Buchanan, M Rachid, RA Parise, JH Beumer, JL Eiseman, RE Schoen, L Zhang and J Yu. Targeting p53-dependent stem cell loss for intestinal chemoprotection. Science Translational Medicine. Feb 7;10(427). pii: eaam7610. doi: 10.1126/scitranslmed.aam7610, 2018.
 
Tong J, P Wang, S Tan, D Chen, Z Nikolovska-Coleska, F Zou, J Yu and L Zhang. Mcl-1 degradation is required for targeted therapeutics to eradicate colon cancer cells. Cancer Research 77: 2512-2521, 2017.
Tong J, S Tan, F Zou, J Yu and L Zhang. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene; 36:787-796, 2016.
Wei L, BJ Leibowitz, X Wang, M Epperly, J Greenberger, L Zhang and J Yu. Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice.  Journal of Clinical Investigation 126:4076-4087, 2016.
 
Misale S, I Bozic, J Tong, A Peraza-Penton, A Lallo, F Baldi, KH Lin, M Truini, L Trusolino, A Bertotti, F Di Nicolantonio, MA Nowak, L Zhang, KC Wood and A Bardelli.  Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.  Nature Communications 2015 Sep 22;6:8305. doi: 10.1038/ncomms9305, 2015.
 
Leibowitz B, W Qiu , ME Buchanan, F Zou, PV Vernon, MP Moyer, XM Yin, RE Schoen, J Yu and L Zhang. BID mediate selective killing of APC-deficient cells in intestinal tumor suppression by non-steroidal anti-inflammatory drugs. Proc. Natl. Acad. Sci. USA.  111:16520-16525, 2014.
Chen D, L Wei, J Yu and L Zhang. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis. Clinical Cancer Research 20: 3472-3484, 2014.
Qiu W, B Wu, X Wang, M Buchanan, MD Regueiro, D Hartman, RE Schoen, J Yu and L Zhang. PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. Journal of Clinical Investigation. 121:1722-1732, 2011.
Qiu W, X Wang, B Leibowitz, H Liu, N Barker, H Okada, N Oue, W Yasui, H Clevers, RE Schoen, J Yu and L Zhang. Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. Proc Natl Acad Sci USA 107:20027-20032, 2010.